Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction
Intervention:   Diagnostic Test: Magnetocardiography
Sponsors:   Genetesis LLC;   St. John Hospital and Medical Center
Recruiting - verified August 2017

Duration of Dual Anti-Platelet Therapy (DUAL-ACS2)

Conditions:   Acute Coronary Syndrome;   Coronary Artery Disease
Interventions:   Other: 3 months dual anti-platelet therapy;   Other: 12 months dual anti-platelet therapy
Sponsors:   University of Edinburgh;   British Heart Foundation
Not yet recruiting - verified August 2017

Optimal Antithrombotic Therapy for Acute Coronary Syndrome Patients Concomitant Atrial Fibrillation Undergoing Polymer-free Drug Eluting Stent Implantation

Conditions:   Acute Coronary Syndrome (ACS);   Non-valvular Atrial Fibrillation (NVAF)
Intervention:   Drug: Triple Antibiotic
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting - verified August 2017

Secondary PRevention Intervention by a Nursing Guide Program (SPRING)

Conditions:   Acute Coronary Syndrome;   Nutrition;   Physical Activity
Intervention:   Behavioral: INTERVENTION GROUP
Sponsor:   University Hospital A Coruña
Active, not recruiting - verified August 2017

Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Interventions:   Drug: Aspirin;   Drug: P2Y12 inhibitor
Sponsor:   Humanitas Hospital, Italy
Recruiting - verified August 2017

The Impact of Early Surgery and Maintenance of Antiplatelet Therapy on Intraoperative Bleeding and Major Adverse Cardiovascular Event After Percutaneous Coronary Intervention

Conditions:   Acute Coronary Syndrome;   Drug-eluting Stent;   Aspirin
Intervention:   Procedure: Non-cardiac surgery
Sponsor:   Seoul National University Hospital
Completed - verified August 2017

Validation of Chinese Version Appropriate Use Criteria for Coronary Revascularization

Conditions:   Appropriate Use Criteria;   Coronary Revascularization
Sponsor:   China National Center for Cardiovascular Diseases
Recruiting - verified August 2017

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists;   Drug: dabigatran (Pradaxa)
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Reducing Acute Coronary Syndrome Patient Delay

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Text+Visual BCT-based intervention;   Behavioral: Text-only BCT intervention;   Behavioral: Leaflet information (control)
Sponsors:   Edinburgh Napier University;   University of Stirling;   University of Aberdeen;   University of Dundee;   The University of New South Wales
Recruiting - verified August 2017

Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma;   Aarne Koskelo Foundation;   Finnish Cultural Foundation
Recruiting - verified August 2017

Mild Therapeutic Hypothermia for Patients With Acute Coronary Syndrome and Cardiac Arrest Treated With PCI

Conditions:   Cardiac Arrest;   Acute Coronary Syndrome
Intervention:   Procedure: Mild Therapeutic Hypothermia (MHT)
Sponsor:   Jacek Kubica
Not yet recruiting - verified August 2017

"Me and My Heart" Study

Condition:   Acute Coronary Syndrome
Interventions:   Device: Active group with MEMS;   Device: Active group without MEMS;   Device: Control group with MEMS;   Device: Control group without MEMS
Sponsor:   AstraZeneca
Recruiting - verified August 2017

The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome

Conditions:   Depression;   Acute Coronary Syndrome
Interventions:   Drug: Melatonin (N-acetyl-5-methoxytryptamine);   Drug: Placebo
Sponsors:   Zealand University Hospital;   Psychiatric Research Unit, Region Zealand, Denmark;   University of Copenhagen;   Pharma Nord
Active, not recruiting - verified August 2017

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Active, not recruiting - verified August 2017

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II

Condition:   Acute Coronary Artery Syndrome
Interventions:   Procedure: Percutaneous coronary intervention;   Procedure: Intravascular ultrasound with virtual histology;   Drug: Atorvastatin or other equivalent dose statin;   Device: LDL-apheresis
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified August 2017

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Sponsor:   AstraZeneca
Active, not recruiting - verified August 2017

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified August 2017

PRevalence, Persistence and prOgnostic ValuE of Sleep Apnea Syndrome in Acute Heart Failure

Conditions:   Sleep Apnea Syndrome;   Heart Failure
Intervention:   Other: polygraphy and ECG
Sponsors:   French Cardiology Society;   ResMed Foundation;   Henri Mondor University Hospital
Recruiting - verified August 2017

The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry

Condition:   Platelet Aggregation Onhibitors
Intervention:   Drug: antiplatelet drugs - P2Y12 antagonists
Sponsor:   Faculty Hospital Kralovske Vinohrady
Recruiting - verified August 2017

The Role of Gut Microbiota in Hypertension

Condition:   Hypertension
Intervention:   Other: Stool Sample and Blood Sample
Sponsors:   University of Florida;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2017

Essential Hypotension and Allostasis Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Sponsor:   CES University
Recruiting - verified August 2017

Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients

Condition:   Acute Myocardial Infarction
Intervention:   Drug: antiplatelet therapy
Sponsor:   Korea University Guro Hospital
Recruiting - verified August 2017

Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis

Conditions:   Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis;   Intermediate Saphenous Vein Graft Lesions
Intervention:   Drug: extended-release niacin (Niaspan)
Sponsors:   North Texas Veterans Healthcare System;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2017

COPES Phase I Randomized Controlled Trial of Treatment For Distress in Heart Disease Patients

Conditions:   Heart Diseases;   Depression
Interventions:   Behavioral: Enhanced depression care;   Behavioral: Referred depression care
Sponsors:   Columbia University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2017